Recombinant Human B-lymphocyte antigen CD19 (CD19), partial,Biotinylated

In Stock
Code CSB-MP004888HU-B
MSDS
Size $596
Order now
Image
  • (Tris-Glycine gel) Discontinuous SDS-PAGE (reduced) with 5% enrichment gel and 15% separation gel.
Have Questions? Leave a Message or Start an on-line Chat

Product Details

Purity
Greater than 95% as determined by SDS-PAGE.
Activity
Not Test
Target Names
Uniprot No.
Research Area
Immunology
Alternative Names
B-lymphocyte surface antigen B4;Differentiation antigen CD19;T-cell surface antigen Leu-12;CD antigen CD19
Species
Homo sapiens (Human)
Source
Mammalian cell
Expression Region
20-291aa
Target Protein Sequence
PEEPLVVKVEEGDNAVLQCLKGTSDGPTQQLTWSRESPLKPFLKLSLGLPGLGIHMRPLAIWLFIFNVSQQMGGFYLCQPGPPSEKAWQPGWTVNVEGSGELFRWNVSDLGGLGCGLKNRSSEGPSSPSGKLMSPKLYVWAKDRPEIWEGEPPCLPPRDSLNQSLSQDLTMAPGSTLWLSCGVPPDSVSRGPLSWTHVHPKGPKSLLSLELKDDRPARDMWVMETGLLLPRATAQDAGKYYCHRGNLTMSFHLEITARPVLWHWLLRTGGWK
Note: The complete sequence including tag sequence, target protein sequence and linker sequence could be provided upon request.
Mol. Weight
57.9 kDa
Protein Length
Partial
Tag Info
C-terminal hFc-Avi-tagged
Form
Liquid or Lyophilized powder
Note: We will preferentially ship the format that we have in stock, however, if you have any special requirement for the format, please remark your requirement when placing the order, we will prepare according to your demand.
Buffer
If the delivery form is liquid, the default storage buffer is Tris/PBS-based buffer, 5%-50% glycerol. If the delivery form is lyophilized powder, the buffer before lyophilization is Tris/PBS-based buffer, 6% Trehalose.
Reconstitution
We recommend that this vial be briefly centrifuged prior to opening to bring the contents to the bottom. Please reconstitute protein in deionized sterile water to a concentration of 0.1-1.0 mg/mL.We recommend to add 5-50% of glycerol (final concentration) and aliquot for long-term storage at -20℃/-80℃. Our default final concentration of glycerol is 50%. Customers could use it as reference.
Troubleshooting and FAQs
Storage Condition
Store at -20°C/-80°C upon receipt, aliquoting is necessary for mutiple use. Avoid repeated freeze-thaw cycles.
Shelf Life
The shelf life is related to many factors, storage state, buffer ingredients, storage temperature and the stability of the protein itself.
Generally, the shelf life of liquid form is 6 months at -20°C/-80°C. The shelf life of lyophilized form is 12 months at -20°C/-80°C.
Lead Time
3-7 business days
Notes
Repeated freezing and thawing is not recommended. Store working aliquots at 4℃ for up to one week.
Datasheet & COA
Please contact us to get it.

Customer Reviews and Q&A

 Customer Reviews

There are currently no reviews for this product.

Submit a Review here

Target Background

Function
Functions as coreceptor for the B-cell antigen receptor complex (BCR) on B-lymphocytes. Decreases the threshold for activation of downstream signaling pathways and for triggering B-cell responses to antigens. Activates signaling pathways that lead to the activation of phosphatidylinositol 3-kinase and the mobilization of intracellular Ca(2+) stores. Is not required for early steps during B cell differentiation in the blood marrow. Required for normal differentiation of B-1 cells. Required for normal B cell differentiation and proliferation in response to antigen challenges. Required for normal levels of serum immunoglobulins, and for production of high-affinity antibodies in response to antigen challenge.
Gene References into Functions
  1. diffuse large B cell lymphoma lacking CD19 or PAX5 expression were more likely to have mutant TP53. PMID: 28484276
  2. The impairment of Bregs and CD19+/BTLA+ cells could play an important pathogenic role in multiple sclerosis (MS). PMID: 27412504
  3. Inhibition of Akt signaling during ex vivo priming and expansion gives rise to CD19CAR T cell populations that display comparatively higher antitumor activity PMID: 28331616
  4. CD19-specific triplebody SPM-1 mediated potent lysis of cancer-derived B cell lines and primary cells from patients with various B-lymphoid malignancies. PMID: 27825135
  5. The increase in CD19+CD24+CD27+ Bregs was closely associated with fasting insulin secretion. PMID: 28440417
  6. The preclinical activity, safety and PK profile support clinical investigation of MGD011 (MGD011 is a CD19 x CD3 DART bispecific protein )as a therapeutic candidate for the treatment of B-cell malignancies PMID: 27663593
  7. this study shows that CD19 isoforms enable resistance to adoptive cellular immunotherapy PMID: 28441264
  8. Anti-CD19-chimeric antigen receptors T cells synergistically exerted collaborative cytotoxicity against primary double-hit lymphoma cells with anti-CD38-chimeric antigen receptors T cells. PMID: 28595585
  9. Two infants with relapsed, refractory B-cell acute lymphoblastic leukemia went into complete remission after being treated with CD19-targeting CAR T cells derived from an unmatched donor PMID: 28193774
  10. These data provide proof-of-principle for the view that newly generated Ab-secreting cells can acquire a mature plasma cell phenotype that is accompanied by loss of CD19 expression at an early stage of differentiation and that aging is not an obligate requirement for a CD19(neg) state to be established. PMID: 28490574
  11. Results indicate the strong efficacy of FLAG-tagged CD19 CAR-T cells in solid and hematological cancer models. PMID: 28410137
  12. The histological observations suggested that the patients represent diverse cases of NHL like mature B-cell type, mature T-cell type and high grade diffuse B-cell type NHL. The findings indicate that patients with NHL may also be analyzed for status of PAX5, CD19 and ZAP70, and their transcriptional and post-translational variants for the differential diagnosis of NHL and therapy. PMID: 27748274
  13. The frequencies of CD19+CD24hiCD38hi B-regulatory lymphocyte were significantly increased in children with beta-thalassemia. PMID: 26852663
  14. a CD45+/CD19 - cell population in bone marrow aspirates correlated with the clinical outcome of patients with mantle cell lymphoma. PMID: 25739938
  15. CD19 is required for TLR9-induced B-cell activation. Hence CD19/PI3K/AKT/BTK is an essential axis integrating BCRs and TLR9 signaling in human B cells. PMID: 26478008
  16. High anti-EBV IgG levels in Crohn's disease are associated with 5-aminosalicylic acid treatment, tonsillectomy, and decrease of CD19(+) cells. PMID: 25914477
  17. We propose that CD81 enables the maturation of CD19 and its trafficking to the membrane by regulating the exit of CD19 from the ER to the pre-Golgi compartment PMID: 25739915
  18. we outline our approach to nonviral gene transfer using the Sleeping Beauty system and the selective propagation of CD19-specific CAR(+) T cells on AaPCs PMID: 25591810
  19. We demonstrate that this motif plays a role in the maturation and recycling of CD19 but in a CD81-independent manner. PMID: 26111452
  20. Studies indicate that anti-CD19 and anti-CD33 bispecific antibodies showed anticancer activity. PMID: 25883042
  21. The synaptic recruitment of lipid rafts is dependent on CD19-PI3K module and cytoskeleton remodeling molecules. PMID: 25979433
  22. gene deficiency results in severe lung disease in French patient PMID: 24684239
  23. propose a multilayer model of plasma cell (PC) memory in which CD19(+) and CD19(-) PC represent dynamic and static components, respectively, permitting both adaptation and stability of humoral immune protection PMID: 25573986
  24. Suppression of innate and adaptive B cell activation pathways by antibody coengagement of FcgammaRIIb and CD19. PMID: 24828435
  25. Human CD19 and CD40L deficiencies impair antibody selection and differentially affect somatic hypermutation. PMID: 24418477
  26. A lower primary CD24(hi) CD27(+) CD19(+) B cells may be an immunologic aspect of new-onset SLE that may be a useful tool to evaluate lupus activity and monitor the response to therapy. PMID: 24286662
  27. higher percentage of CD19+ cells in patients with acute appendicitis; decreases after appendectomy PMID: 24375063
  28. CD20 and CD19 targeting vectors induce activating stimuli in resting B lymphocytes, which most likely renders them susceptible for lentiviral vector transduction. PMID: 24244415
  29. Latently infected cells from patients with multiple sclerosis, treated with natalizumab, initiate differentiation to CD19+ cells that favor growth of JC polyomavirus. PMID: 24664166
  30. This inhibitory function of FcgammaRIIB in impairing the spatial-temporal colocalization of BCR and CD19 microclusters in the B cell immunological synapse may help explain the hyper-reactive features of systemic lupus erythematosus PMID: 24790152
  31. Considering that the CD19 complex regulates the events following antigen stimulation, the change in CD19 complex detected in transient hypogammaglobulinemia of infancy may be related to insufficiency of antibody production. PMID: 22820757
  32. CD19 emerged as a powerful predictor of event-free and overall survival in CNS diffuse large B-cell lymphomas and Burkitt lymphomas PMID: 24501214
  33. these data demonstrate that CD19 and CD32b differentially inhibit B cell expansion and plasma cell differentiation, depending on the nature of the activating stimuli, when engaged with monospecific Abs. PMID: 24442430
  34. CD19 expression in acute leukemia is not restricted to the cytogenetically aberrant populations. PMID: 23193950
  35. CD19 is expressed very early in B-cell development and is a good target for antibody therapy in lymphoblastic leukemia. PMID: 23277329
  36. The resulting CD19(high)/CD19(low) B-cell ratio increased markedly in the milk-tolerant group. PMID: 22563781
  37. Use of c-Myc transgenic mice deficient in CD19 expression leads to identification of a c-Myc:CD19 regulatory loop that positively influences B cell transformation and lymphoma progression. PMID: 22826319
  38. Results obtained through a large cohort of European caucasian patients with systemic sclerosis do not support the contribution of CD19, CD20, CD22, CD24 variants to the genetic susceptibility. PMID: 21961844
  39. Data indicate that among MDS cases, CD15+ and CD19+ cell TLs were positively correlated, and PBL TL was was not associated with hTERT genotype. PMID: 21635204
  40. Studies showed the qualitative and quantitative expression of four target surface antigens, CD19, CD20, CD22, and CD33, for which MoAbs are currently available for clinical use, in ALL. PMID: 21348573
  41. Data show that CD45+CD19- MCL-ICs play a role in the drug resistance of MCL, and this drug resistance was largely due to quiescent properties with enriched ABC transporters. PMID: 21599592
  42. A missense mutation of CD19 in the conserved tryptophan 41 in immunoglobulin superfamily domain resulted in antibody deficiency. PMID: 21330302
  43. Data suggest that CD19 and CD33 are present on the surface of the leukemic cell lines such that they can be connected by a single sctb molecule. PMID: 21081841
  44. CD23 and CD19 are important factors that associated with serum total IgE in the pathogenesis of allergic rhinitis. PMID: 20359104
  45. binding sites for CD19 and CD16 have a role in antibody-dependent cellular cytotoxicity against B-lymphoid tumor cells PMID: 21339041
  46. Heterozygous loss of CD19 causes some changes in the naive B-cell compartment, but overall in vivo B-cell maturation or humoral immunity is not affected. PMID: 20445561
  47. Altered CD19/CD22 balance in Egyptian children and adolescents with systemic lupus erythematosus. PMID: 20726320
  48. The CD27(+) B-cell population was found to highly express CXCR3 in chronic hepatitis C (CHC), thus suggesting that the CD27(+) B-cell population was recruited from peripheral blood to the inflammatory site of the liver of CHC. PMID: 20377416
  49. Aberrant expression of CD19 in acute myeloblastic leukemia with t(8;21) involves a poised chromatin structure and PAX5. PMID: 20208555
  50. Studies indicate taht B lymphocytes proliferated when approximately 100 antigen receptors per cell, 0.03 percent of the total, were coligated with CD19. PMID: 20164433

Show More

Hide All

Involvement in disease
Immunodeficiency, common variable, 3 (CVID3)
Subcellular Location
Cell membrane; Single-pass type I membrane protein. Membrane raft; Single-pass type I membrane protein.
Tissue Specificity
Detected on marginal zone and germinal center B cells in lymph nodes. Detected on blood B cells (at protein level).
Database Links

HGNC: 1633

OMIM: 107265

KEGG: hsa:930

STRING: 9606.ENSP00000437940

UniGene: Hs.652262

CUSABIO guaranteed quality
icon of phone
Call us
301-363-4651 (Available 9 a.m. to 5 p.m. CST from Monday to Friday)
icon of address
Address
7505 Fannin St., Ste 610, Room 7 (CUBIO Innovation Center), Houston, TX 77054, USA
icon of social media
Join us with

Subscribe newsletter

Leave a message

* To protect against spam, please pass the CAPTCHA test below.
CAPTCHA verification
© 2007-2024 CUSABIO TECHNOLOGY LLC All rights reserved. 鄂ICP备15011166号-1
Place an order now

I. Product details

*
*
*
*

II. Contact details

*
*

III. Ship To

*
*
*
*
*
*
*

IV. Bill To

*
*
*
*
*
*
*
*